Tirzepatide dosage rose in small steps during studies
You'll see what phase 3, the last large studies, tested and how long half took to leave. I'd take your amount questions to your prescriber.
Contents
Tirzepatide dosage started low and rose slowly
These amounts came from phase 3, the last large study stage, and the FDA drug record. They show what researchers used, not a plan for you.
Each large phase 3 study began with a 2.5 mg weekly shot for the first 4 weeks. The amount then rose to 5 mg each week [2][5].
From 5 mg, study staff could add 2.5 mg every 4 weeks. No main phase 3 study went above 15 mg.
The first 2.5 mg helped people get used to the drug. It was below the first treatment amount of 5 mg [14].
The FDA record lists 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly shots [14]. Study staff used the belly, upper arm, or thigh.
Half the tirzepatide left before the next weekly shot
A 2024 review measured tirzepatide in blood from 4,344 people in phase 3 studies [10]. The results explain why researchers gave one shot each week:
- Time until half was gone: about 5.4 days, usually 4.9–5.8 days
- Amount of the shot reaching blood: about 80%
- Time of the highest blood level: 8–72 hours after a shot
- For a person weighing 70 kg: the drug still traveled mainly through the blood
- Amount held by a blood protein: about 99%, which slowed its exit
- After more shots: blood levels rose, then stopped climbing
- Time until the level stopped climbing: about 4 weeks of weekly shots
- Why a weekly shot worked: some drug remained through the 7-day gap. Age, sex, weight, and kidney health didn't change blood levels enough to alter study amounts [10].
A common blood protein slowed the drug's exit
About half left over several days, so some remained across a 7-day gap. A small fat-like part helps tirzepatide hold onto albumin, a common protein in blood [9].
The fat-like part joins at part 20 of the drug. You can't feel the link, but it kept the medicine from leaving within minutes.
Most tirzepatide left within about a month
About half the drug left every 5 days, or 120 hours. Most was gone after 4–5 such spans, about 25–27 days after the last shot [10].
With weekly shots, blood levels stopped climbing after about 4 weeks. The level was then higher than after one shot because some drug remained.
After stopping, the amount in blood kept falling on that 5.4-day clock. By 4 weeks, less than 10% of the amount present before stopping was expected to remain.
Some studies used that wait before another medicine or certain tests [10][14]. The papers don't name one wait that fits every drug or test, so ask your doctor about your own plans.
Tirzepatide changed blood sugar before weight
Blood sugar after meals changed during the first week [2]. The scale showed a study-proven drop by weeks 4–8.
The largest weight loss came at week 72 and hadn't stopped at the highest amount [5]. That doesn't mean everyone lost weight at the same pace.
The stomach slowed most after the first shot, then neared its prior speed [10]. You may notice stronger fullness early on.
Less hunger from GLP-1 and the second gut hormone lasted while people kept taking tirzepatide [22]. Ask when your prescriber will check how GLP-1 and the second hormone affected your weight and blood sugar.
Phase 3 study staff raised tirzepatide amounts in steps
The escalation schedule used across all major SURPASS and SURMOUNT phase 3 trials [2][5][6][7][14]:
| Week Range | Dose |
|---|---|
| Weeks 1–4 | 2.5 mg once weekly |
| Weeks 5–8 | 5 mg once weekly |
| Weeks 9–12 | 7.5 mg once weekly (if tolerated; 5 mg continued if not) |
| Weeks 13–16 | 10 mg once weekly |
| Weeks 17–20 | 12.5 mg once weekly |
| Week 21+ | 15 mg once weekly (maximum dose) |
In SURMOUNT trials, "maximum tolerated dose" was defined as the highest dose at which participants did not experience intolerable GI adverse events — allowing participants who could not escalate to stay at a lower therapeutic dose. Both 10 mg and 15 mg were evaluated as the maximum dose in trials where individual tolerability limited escalation [5][7].
See tirzepatide side effects for GI tolerability data, or tirzepatide clinical trial data for the efficacy outcomes at each dose level.
One practice note sits outside the trial record itself: this escalation schedule is clinician-managed, not self-directed. Tirzepatide is a prescription compound in the United States, and the decisions the protocol leaves open — whether a participant steps to 7.5 mg or holds at 5 mg — were made by study clinicians gating each increase on tolerability. The same structure carries into practice through licensed telehealth: at Promise Peptides (mypromise.com), for example, prescribing clinicians set and adjust the tirzepatide titration schedule rather than leaving dose changes to the patient.
Study shots stayed cold and went under the skin
The FDA record says to keep tirzepatide at 2–8°C, near fridge temperature [14]. It may stay at room temperature, no warmer than 30°C, for up to 21 days.
Light can damage the drug, and freezing can ruin it. Study shots went into the belly, upper arm, or thigh, with the spot changed each time.
Researchers didn't study shots into a vein or muscle. About half the drug remained after 5.4 days, and about 80% of the shot reached the blood [10][14].